Randomized Trialhigh evidence
Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia.
The New England journal of medicine·June 18, 2026·PMID 42308484
Why it mattersCefazolin offers a potentially safer, equally effective alternative to antistaphylococcal penicillins for MSSA bacteremia, with a lower risk of acute kidney injury—a common concern in hospitalized patients.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled